jimki

Profile of Drug-Resistant Tuberculosis (DR-TB) Patients with Chronic Obstructive Pulmonary Disease (COPD) in Dr. H. Abdul Moeloek General Hospital Lampung Province

Authors

  • Afia Farah Nabila

    Fakultas Kedokteran Universitas Lampung
  • Dr. dr. Tri Umiana Soleha, S.Ked., M.Kes

    Fakultas Kedokteran Universitas Lampung
  • dr. Chicy Widya Morfi, Sp.P

    Fakultas Kedokteran Universitas Lampung

DOI:

https://doi.org/10.53366/jimki.v12i3.1094

Keywords:

comorbidity, COPD, drug resistance , DR-TB, tuberculosis

Abstract

Background: Drug-resistant tuberculosis (DR-TB) is an increasingly complex health issue, especially when accompanied by chronic obstructive pulmonary disease (COPD) comorbidity, which can exacerbate lung conditions, affect therapeutic response, and reduce treatment success. This study aims to describe the characteristics of DR-TB patients with COPD comorbidity at RSUD Dr. H. Abdul Moeloek from 2022 to 2024.

Method: This study utilized a retrospective descriptive design. Data used were secondary data from patient medical records. Univariate analysis was performed to describe subject characteristics.

Results: Among 46 patients, the majority were male (78.3%) aged 41–60 years (50%). RR-TB classification (76.1%) and long-term regimens (78.3%) dominated the findings. Therapeutic outcomes recorded 54.3% cured, 30.4% treatment completed, 8.7% failed, and 6.5% deceased.

Discussion: DR-TB patients with COPD are more frequently observed in middle-aged males due to smoking exposure and occupational factors. The majority were classified as RR-TB, consistent with gradual resistance patterns. Long-term regimens were preferred as they are considered safer for lung function. Although COPD aggravates the condition, therapy remains likely to succeed with appropriate drug selection and patient adherence.

Conclusion: DR-TB patients with COPD comorbidity are generally middle-aged males with a relatively good proportion of treatment success. Appropriate regimen selection and strict monitoring are required to optimize treatment outcomes.

References

Farrar J, Hotez PJ, Junghanss T, Kang G, Lallo D, White NJ, et al. Manson’s Tropical Diseases 24th Edition. 24th ed. Elsevier; 2023.

WHO. 2024 Global tuberculosis report. Geneva: World Health Organization; 2024.

Kemenkes. Laporan Program Penanggulangan Tuberkulosis Tahun 2023. Jakarta: Kementrian Kesehatan RI; 2024.

Starshinova A, Nazarenko M, Belyaeva E, Chuzhov A, Osipov N, Kudlay D. Assessment of Comorbidity in Patients with Drug-Resistant Tuberculosis. Pathogens. 2023;12(12):1–13.

Gai X, Allwood B, Sun Y. Advances in the awareness of tuberculosis-associated chronic obstructive pulmonary disease. Chinese Med J Pulm Crit Care Med. 2024;2(4):250–6.

Kim T, Choi H, Kim SH, Yang B, Han K, Jung JH, et al. Increased Risk of Incident Chronic Obstructive Pulmonary Disease and Related Hospitalizations in Tuberculosis Survivors: A Population-Based Matched Cohort Study. J Korean Med Sci. 2024;39(11):1–15.

Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis : mechanistic and evolutionary perspectives. 2017;(March):354–73.

Hosu MC, Faye LM, Apalata T. Comorbidities and Treatment Outcomes in Patients Diagnosed with Drug-Resistant Tuberculosis in Rural Eastern Cape Province, South Africa. Diseases. 2024;12(11).

Published

2026-02-20

How to Cite

Profile of Drug-Resistant Tuberculosis (DR-TB) Patients with Chronic Obstructive Pulmonary Disease (COPD) in Dr. H. Abdul Moeloek General Hospital Lampung Province. (2026). JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 12(3), 1443-1452. https://doi.org/10.53366/jimki.v12i3.1094